Maternal COVID-19 Vaccination and Its Potential Impact on Fetal and Neonatal Development DOI Creative Commons
Niel A. Karrow, Umesh K. Shandilya, Steven Pelech

et al.

Vaccines, Journal Year: 2021, Volume and Issue: 9(11), P. 1351 - 1351

Published: Nov. 18, 2021

Vaccines have been developed under accelerated timelines to combat the COVID-19 pandemic caused by SARS-CoV-2 coronavirus. Although they are considered best approach for preventing mortality, when assessing safety of these vaccines, pregnant women not included in clinical trials. Thus, vaccine this demographic, as well developing fetus and neonate, remains be determined. A global effort has underway encourage get vaccinated despite uncertain risk posed them their offspring. Given this, post-hoc data collection, potentially years, will required determine outcomes vaccination on next generation. Most reactions include injection site erythema, pain, swelling, fatigue, headache, fever lymphadenopathy, which may sufficient affect fetal/neonatal development. In review, we explored components first-generation viral vector mRNA vaccines that believed contribute adverse negatively impact fetal neonatal We followed with a discussion potential using an ovine model explore long-term during prenatal periods.

Language: Английский

Enhanced Humoral and Cellular Immune Responses Elicited by Salmonella Flagellin-Adjuvanted SARS-CoV-2 S1 Subunit Vaccine DOI
Song Li,

Yaodan Cui,

Qiaoju Wang

et al.

Viral Immunology, Journal Year: 2025, Volume and Issue: unknown

Published: March 24, 2025

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, has been spreading and changing globally. Adjuvant-based vaccines can improve vaccine protection by enhancing immune response. Bacterial flagellin is a potent adjuvant promotes protective responses. Here, we successfully expressed purified S1 subunit of SARS-CoV-2. The adjuvanticity (FliC) Salmonella Typhimurium in mice was determined combining it with recombinant vaccine. FliC-adjuvanted could induce significantly enhanced S1-specific Immunoglobulin G (IgG), IgG1 IgG2a titers, SARS-CoV-2-neutralizing antibodies, levels Th1 type (TNF-α IFN-γ) Th2 (Interleukin-5 (IL-5), IL-4, IL-10, IL-13) cytokines splenocytes compared alone group. Additionally, titers IgG antibodies FliC group maintain high level for at least months. These results indicated trigger strong humoral cellular responses, which promote ongoing development COVID-19 vaccines.

Language: Английский

Citations

0
Development of an ELISA Test with High Diagnostic Accuracy for SARS-COV-2 Using Recombinant Nucleocapsid Protein Expressed in E. coli DOI

Mahsa Darestanifarahani,

F. Baba Mahmoudi, Ali Mohammadi

et al.

Molecular Biotechnology, Journal Year: 2025, Volume and Issue: unknown

Published: April 7, 2025

Language: Английский

Citations

0
Host–Pathogen Interaction Interface: Promising Candidate Targets for Vaccine-Induced Protective and Memory Immune Responses DOI Creative Commons
Gloria Guillermina Guerrero Manríquez, Vicente Madrid‐Marina, Aurora Martínez-Romero

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 418 - 418

Published: April 16, 2025

Vaccine formulations are a successful strategy against pathogen transmission because vaccine candidates induce effective and long-lasting memory immune responses (B CD4+ T cells) at systemic mucosal sites. Extracellular vesicles of lipoproteins, bioactive compounds from plants invertebrates (sponges) encapsulated in liposomes, glycoproteins can target these The developed mimic microbial pathogens way that successfully links the innate adaptive responses. In addition, vaccines plus adjuvants promote maintain an inflammatory response. this review, we aimed to identify host–pathogen interface as rich source candidate targets for vaccine-induced protective

Language: Английский

Citations

0
Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern DOI Creative Commons
Ankita Saha, Sounak Ghosh Roy, Richa Dwivedi

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 424 - 424

Published: April 17, 2025

Vaccination has been instrumental in curbing the transmission of SARS-CoV-2 and mitigating severity clinical manifestations associated with COVID-19. Numerous COVID-19 vaccines have developed to this effect, including BioNTech-Pfizer Moderna’s mRNA vaccines, as well adenovirus vector-based such Oxford–AstraZeneca. However, emergence new variants subvariants SARS-CoV-2, characterized by enhanced transmissibility immune evasion, poses significant challenges efficacy current vaccination strategies. In review, we aim comprehensively outline landscape emerging concern (VOCs) sub-lineages that recently surfaced post-pandemic years. We assess effectiveness existing their booster doses, against these subvariants, BA.2-derived sub-lineages, XBB BA.2.86 (Pirola). Furthermore, discuss latest advancements vaccine technology, multivalent pan-coronavirus approaches, along development several next-generation coronavirus exosome-based, virus-like particle (VLP), mucosal, nanomaterial-based vaccines. Finally, highlight key critical areas for future research address evolving threat develop strategies combating viral threats, thereby improving preparedness pandemics.

Language: Английский

Citations

0
COVID-19 Vaccines: Current Conditions and Future Prospects DOI Creative Commons
Tarek Zieneldien, Janice Kim, J. Cao

et al.

Biology, Journal Year: 2021, Volume and Issue: 10(10), P. 960 - 960

Published: Sept. 26, 2021

It has been over a year since SARS-CoV-2 was first reported in December of 2019 Wuhan, China. To curb the spread virus, many therapies and cures have tested developed, most notably mRNA DNA vaccines. Federal health agencies (CDC, FDA) approved emergency usage these S gene-based vaccines with intention minimizing any further loss lives infections. is crucial to assess which are efficacious by examining their effects on immune system, providing considerations for new technological vaccine strategies future. This paper provides an overview current mechanisms action, technologies utilized manufacturing vaccines, limitations this field emerging data. Although popular COVID-19 proven effective, time will be main factor dictating able best address mutations future infection.

Language: Английский

Citations

22
mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2 DOI Creative Commons

Yingqi Jin,

C. Hou,

Yonghao Li

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 12

Published: Jan. 21, 2022

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health the world economy. The development of safe effective vaccines crucial to prevention control an epidemic. As emerging technology, mRNA vaccine widely used for infectious has significant safety, efficacy, production. It received support funding from many pharmaceutical enterprises becomes one main technologies preventing COVID-19. This review introduces current status SARS-CoV-2 vaccines, specifically focusing on challenges developing against SARS-CoV-2, discusses relevant strategies.

Language: Английский

Citations

16
RETRACTED: Safety and immunogenicity of a recombinant receptor‐binding domain‐based protein subunit vaccine (Noora vaccine™) against COVID‐19 in adults: A randomized, double‐blind, placebo‐controlled, Phase 1 trial DOI
Jafar Salimian, Ali Ahmadi, Jafar Amani

et al.

Journal of Medical Virology, Journal Year: 2022, Volume and Issue: 95(2)

Published: Aug. 27, 2022

Abstract The development of a safe and effective vaccine is essential to protect populations against coronavirus disease 2019 (COVID‐19). There are several candidates under investigation with different mechanisms action. In the present study, we have evaluated safety immunogenicity recombinant receptor‐binding domain (RBD)‐based protein subunit (Noora vaccine) COVID‐19 in adults. This Phase 1 trial randomized, double‐blind, placebo‐controlled study evaluate RBD‐based healthy adults volunteers. Eligible participants were included this after evaluating their health status considering exclusion criteria. They then randomized into three groups received doses (80 µg, 120 placebo) on Days 0, 21, 35. Primary outcomes including solicited, unsolicited, medically attended adverse events recorded during study. Secondary humoral cellular immunity (including anti‐RBD IgG antibody neutralizing antibody) measured 28, 35, 42, 49 by using ELISA kit Virus Neutralization Test (VNT) was performed day 49. Totally 70 cases 60 them completed Safety assessments showed no severe events. Local pain at injection site occurred 80% vaccinated Induration redness other reactions vaccine. significant difference between studied regarding reactions. Anti‐RBD assessment seroconversion comparison placebo group (80%, 100% respectively, p < 0.001). panel also mild moderate induction TH1 responses VNT 78% seroprotection. results acceptable without serious seroconversions panel. dose 80 µg an appropriate for next phases trial.

Language: Английский

Citations

16
Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast DOI Open Access
Alessio Danilo Inchingolo, Giuseppina Malcangi, Sabino Ceci

et al.

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(15), P. 8485 - 8485

Published: July 30, 2022

The recent COVID-19 pandemic produced a significant increase in cases and an emergency state was induced worldwide. current knowledge about the disease concerning diagnoses, patient tracking, treatment protocol, vaccines provides consistent contribution for primary prevention of viral infection decreasing severity SARS-CoV-2 disease. aim present investigation to produce general overview findings disease, interaction mechanisms with host, therapies vaccines' immunization findings. A literature order evaluate state-of-art prognoses, therapies, prevention. Concerning virus binds target its Spike proteins on surface uses it as anchor. protein targets ACE2 cell receptor enters into cells by using special enzyme (TMPRSS2). Once virion is quietly accommodated, releases RNA. Proteins RNA are used Golgi apparatus more viruses that released. different protocols have been developed observance comorbidity reduction mortality rate. Currently, currently phase IV but remarkable difference efficiency has detected variants. Among many questions this state, one recurs most knowing why some people become seriously ill than others who instead contract if trivial flu. More studies necessary investigate variant.

Language: Английский

Citations

15
Mining Textual and Imagery Instagram Data during the COVID-19 Pandemic DOI Creative Commons
Dimitrios Amanatidis, Ifigeneia Mylona, Irene Kamenidou

et al.

Applied Sciences, Journal Year: 2021, Volume and Issue: 11(9), P. 4281 - 4281

Published: May 9, 2021

Instagram is perhaps the most rapidly gaining in popularity of photo and video sharing social networking applications. It has been widely adopted by both end-users organizations, posting their personal experiences or expressing opinion during significant events periods crises, such as ongoing COVID-19 pandemic search for effective vaccine treatment. We identify three major companies involved research extract posts, after vaccination started, well users’ reception using respective hashtags, constructing datasets. Statistical differences regarding are initially presented, on textual, visual features, i.e., image classification transfer learning. Appropriate preprocessing English language posts content analysis subsequently performed, automatically annotating one four intent classes, thus facilitating training nine classifiers a potential application capable predicting user’s intent. By designing carrying out controlled experiment we validate that resulted algorithms’ accuracy ranking significant, identifying two best performing algorithms; this further improved ensemble techniques. Finally, polarity leveraging convolutional neural network, reveals rather neutral to negative sentiment, with highly polarized user posts’ distributions.

Language: Английский

Citations

20
Looking to the future: is a universal coronavirus vaccine feasible? DOI Open Access
Vipin M. Vashishtha, Puneet Kumar

Expert Review of Vaccines, Journal Year: 2021, Volume and Issue: 21(3), P. 277 - 280

Published: Dec. 30, 2021

Language: Английский

Citations

18